The Institute for Clinical and Economic Review (ICER) is planning to lower its "value-based" pricing benchmark for Amgen Inc.'s Repatha (evolocumab) following the recent release of final results of the FOURIER cardiovascular outcomes trial on the drug.
Announced in mid-March, FOURIER results showed a 15% reduction in a composite of major adverse cardiovascular events in patients with...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?